AxoGen (AXGN -20.8%) is down on more than triple normal volume after its announcement of preliminary Q4 2018 and full-year results.
Q4 revenue was at least $23.4M, up 38% yoy but potentially shy of $24.2M consensus. Full-year revenue was at least $83.9M, also potentially short of $84.6M consensus.
2019 outlook: revenue growth of at least 35%. Gross margin to remain above 80%.
#JPM19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.